Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis

Mariangela Sciandra, Giovanna Borriello, Alberto Gajofatto, Paola Grossi, Antonio Cortese, Alvino Bisecco, Gina Ferrazzano, Matteo Lucchini, Antonio Carotenuto, Clara Grazia Chisari, Paola Valentino, Maria Teresa Ferrò, Erica Curti, Antonio Gallo, Elisabetta Signoriello, Francesca Gobbin, Aurora Zanghì, Maddalena Sparaco, Vincenzo Bresciamorra, Elena TsantesGian Marco Abbadessa, Roberta Lanzillo, Ernesto Siena, Emanuele D’Amico, Alessia Giugno, Emanuele D’Amico, Alessia Giugno, Emanuele D’Amico, Maria Buccafusca, Giacomo Lus, Simona Bonavita, Massimiliano Mirabella, Franco Granella, Luigi Maria Edoardo Grimaldi, Francesco Patti, Graziella Callari

Risultato della ricerca: Articlepeer review

6 Citazioni (Scopus)

Abstract

The introduction of oral disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS) changed the therapeutic landscape and algorithms of RRMS treatment (1). In Europe, dimethyl fumarate (DMF) and teriflunomide (TRF) are approved as first-line agents and are often used as the initial therapeutic choice (2, 3). Pivotal trials showed the efficacy of both DMTs on controlling clinical relapses, disability accrual and magnetic resonance imaging (MRI) activity (4-8). Both DMTs had overall good tolerability. There have been no head-to-head randomized trials to compare these two DMTs; however, several real-world evidence (RWE) studies have compared DMF and TRF and provided useful information to guide the selection of either drug for MS patients (9, 10). Although different statistical methods were used, both drugs demonstrated an ability to control disease activity (11-13). In some RWE studies, patients on DMF had a lower relapse rate and a higher relapse-free survival time (11, 12). In this registry-based nationwide cohort Cox-model study, we compared the clinical and radiological activity between patients treated with DMF or TRF.
Lingua originaleEnglish
Numero di pagine22
RivistaJournal of Neurology
Stato di pubblicazionePublished - 2020

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Fingerprint Entra nei temi di ricerca di 'Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis'. Insieme formano una fingerprint unica.

Cita questo